In Reply: Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus Infections

Pediatr Infect Dis J. 2017 Mar;36(3):348-349. doi: 10.1097/INF.0000000000001433.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal
  • Antiviral Agents
  • Hospitalization
  • Humans
  • Infant
  • Palivizumab*
  • Respiratory Syncytial Virus Infections*

Substances

  • Antibodies, Monoclonal
  • Antiviral Agents
  • Palivizumab